• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miRNAs 在乳腺导管原位癌进展中的功能作用。

Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.

机构信息

Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

出版信息

Am J Pathol. 2019 May;189(5):966-974. doi: 10.1016/j.ajpath.2018.06.025. Epub 2018 Sep 29.

DOI:10.1016/j.ajpath.2018.06.025
PMID:30273605
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6521886/
Abstract

miRNAs are small RNAs that influence gene expression by targeting mRNAs. Depending on the function of their target genes, miRNAs may regulate the expression of oncogenes and tumor suppressors, thereby contributing to the promotion or inhibition of tumor progression. Ductal carcinoma in situ (DCIS), although often diagnosed as breast cancer, is a potential precursor to invasive ductal carcinoma. Many of the genetic events required for the invasive progression of DCIS occur at the preinvasive stage, and these events include changes in the expression of miRNAs. Aberrant expression of miRNAs can influence specific oncogenic or tumor-suppressive pathways required for breast cancer progression. miRNAs in DCIS have been shown to influence hormone signaling, cell-cell adhesion, epithelial-to-mesenchymal transition, transforming growth factor β signaling, maintenance of cancer stem cells, and modulation of the extracellular matrix. Additionally, extracellular DCIS miRNAs, such as those found in exosomes, may promote invasive progression by modifying the tumor microenvironment. Here, we review the miRNAs that have been identified in DCIS and how they may contribute to the progression to invasive disease. We also touch on the current state of miRNA therapy development, including the current challenges, and discuss the key future perspectives for research into miRNA function for the purpose of miRNA therapy development for DCIS.

摘要

miRNAs 是一种通过靶向 mRNAs 影响基因表达的小 RNA。根据其靶基因的功能,miRNAs 可能调节癌基因和肿瘤抑制基因的表达,从而促进或抑制肿瘤的进展。导管原位癌 (DCIS) 虽然常被诊断为乳腺癌,但它是浸润性导管癌的潜在前体。DCIS 浸润进展所需的许多遗传事件发生在侵袭前阶段,这些事件包括 miRNA 表达的变化。miRNA 的异常表达会影响乳腺癌进展所需的特定致癌或肿瘤抑制途径。已经证明,DCIS 中的 miRNAs 可以影响激素信号、细胞间黏附、上皮-间充质转化、转化生长因子 β 信号、维持癌症干细胞和调节细胞外基质。此外,细胞外 DCIS miRNAs,如外泌体中的 miRNAs,可能通过改变肿瘤微环境来促进浸润进展。在这里,我们综述了在 DCIS 中发现的 miRNAs 及其如何促进浸润性疾病的进展。我们还介绍了 miRNA 治疗开发的现状,包括当前的挑战,并讨论了 miRNA 功能研究的关键未来展望,旨在为 DCIS 的 miRNA 治疗开发提供依据。

相似文献

1
Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.miRNAs 在乳腺导管原位癌进展中的功能作用。
Am J Pathol. 2019 May;189(5):966-974. doi: 10.1016/j.ajpath.2018.06.025. Epub 2018 Sep 29.
2
miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.miRNAs 作为预测导管原位癌进展的生物标志物。
Am J Pathol. 2018 Mar;188(3):542-549. doi: 10.1016/j.ajpath.2017.11.003. Epub 2017 Dec 12.
3
Role of deregulated microRNAs in breast cancer progression using FFPE tissue.使用 FFPE 组织研究非调控 microRNAs 在乳腺癌进展中的作用。
PLoS One. 2013;8(1):e54213. doi: 10.1371/journal.pone.0054213. Epub 2013 Jan 23.
4
Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.PLC-β2 在非侵袭性乳腺肿瘤细胞中的异位表达对恶性进展起到保护作用,并与 miR-146a 的失调相关。
Mol Carcinog. 2019 May;58(5):708-721. doi: 10.1002/mc.22964. Epub 2019 Jan 16.
5
Subtype-specific micro-RNA expression signatures in breast cancer progression.乳腺癌进展中的亚型特异性微小RNA表达特征
Int J Cancer. 2016 Sep 1;139(5):1117-28. doi: 10.1002/ijc.30142. Epub 2016 May 9.
6
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.精准医学时代的导管原位癌生物标志物:当前和未来基于分子的检测。
Am J Pathol. 2019 May;189(5):956-965. doi: 10.1016/j.ajpath.2018.08.020. Epub 2018 Oct 29.
7
Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma through activation of TGFβ signaling.肿瘤相关肌上皮细胞通过激活转化生长因子β信号通路促进导管癌的侵袭进展。
J Biol Chem. 2017 Jul 7;292(27):11466-11484. doi: 10.1074/jbc.M117.775080. Epub 2017 May 16.
8
Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.原位、浸润性和淋巴管血管侵犯乳腺癌之间差异 microRNA 表达谱分析:一项初步研究。
Clin Exp Metastasis. 2018 Feb;35(1-2):3-13. doi: 10.1007/s10585-017-9868-4. Epub 2017 Dec 6.
9
Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.在乳腺癌前病变中,miRNA 的表达及其基因靶标失调。
Breast Cancer Res. 2011 Mar 4;13(2):R24. doi: 10.1186/bcr2839.
10
Identification of microRNAs in Nipple Discharge as Potential Diagnostic Biomarkers for Breast Cancer.乳头溢液中微小RNA作为乳腺癌潜在诊断生物标志物的鉴定
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S536-44. doi: 10.1245/s10434-015-4586-0. Epub 2015 May 15.

引用本文的文献

1
Epigenetic regulation of breast ductal carcinoma in situ by miR-217 through DNMT1 and Hedgehog-GLI pathway.miR-217通过DNMT1和Hedgehog-GLI途径对乳腺导管原位癌的表观遗传调控
J Cell Commun Signal. 2025 Sep 3;19(3):e70030. doi: 10.1002/ccs3.70030. eCollection 2025 Sep.
2
miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.miR-145、miR-205 和 miR-451:参与乳腺原位癌向浸润性癌进展的潜在肿瘤抑制因子。
Breast Cancer. 2022 Sep;29(5):814-824. doi: 10.1007/s12282-022-01359-9. Epub 2022 Apr 22.
3
Insights Into Exosomal Non-Coding RNAs Sorting Mechanism and Clinical Application.外泌体非编码RNA分选机制及临床应用的见解
Front Oncol. 2021 Apr 27;11:664904. doi: 10.3389/fonc.2021.664904. eCollection 2021.
4
Identification of genes and miRNA associated with idiopathic recurrent pregnancy loss: an exploratory data mining study.与特发性复发性妊娠丢失相关的基因和 miRNA 的鉴定:一项探索性数据挖掘研究。
BMC Med Genomics. 2020 Jun 1;13(1):75. doi: 10.1186/s12920-020-00730-z.
5
Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.比较 HER-2 阴性和 HER-2 阳性细胞的 MicroRNA 图谱,验证 miR-362-5p/Sema3A 是三阴性乳腺癌的特征性分子变化。
Dis Markers. 2019 Dec 16;2019:6057280. doi: 10.1155/2019/6057280. eCollection 2019.
6
Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication.乳腺癌中的非编码RNA:细胞内与细胞间通讯
Noncoding RNA. 2018 Dec 12;4(4):40. doi: 10.3390/ncrna4040040.

本文引用的文献

1
Metazoan MicroRNAs.后生动物 MicroRNAs。
Cell. 2018 Mar 22;173(1):20-51. doi: 10.1016/j.cell.2018.03.006.
2
Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?肿瘤浸润淋巴细胞与乳腺导管原位癌:是敌是友?
Mod Pathol. 2018 Jul;31(7):1012-1025. doi: 10.1038/s41379-018-0030-x. Epub 2018 Feb 20.
3
MicroRNA-182 downregulates Wnt/β-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9.微小RNA-182通过靶向HOXA9下调Wnt/β-连环蛋白信号通路,抑制人骨肉瘤细胞增殖并促进其凋亡。
Oncotarget. 2017 Sep 22;8(60):101345-101361. doi: 10.18632/oncotarget.21167. eCollection 2017 Nov 24.
4
miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.miRNAs 作为预测导管原位癌进展的生物标志物。
Am J Pathol. 2018 Mar;188(3):542-549. doi: 10.1016/j.ajpath.2017.11.003. Epub 2017 Dec 12.
5
Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.原位、浸润性和淋巴管血管侵犯乳腺癌之间差异 microRNA 表达谱分析:一项初步研究。
Clin Exp Metastasis. 2018 Feb;35(1-2):3-13. doi: 10.1007/s10585-017-9868-4. Epub 2017 Dec 6.
6
Cancer stem cells revisited.癌症干细胞再探。
Nat Med. 2017 Oct 6;23(10):1124-1134. doi: 10.1038/nm.4409.
7
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.治疗性微小RNA和小干扰RNA:作为新一代药物从实验室走向临床
Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143. doi: 10.1016/j.omtn.2017.06.005. Epub 2017 Jun 12.
8
Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma through activation of TGFβ signaling.肿瘤相关肌上皮细胞通过激活转化生长因子β信号通路促进导管癌的侵袭进展。
J Biol Chem. 2017 Jul 7;292(27):11466-11484. doi: 10.1074/jbc.M117.775080. Epub 2017 May 16.
9
Engineering exosomes as refined biological nanoplatforms for drug delivery.将外泌体工程化为用于药物递送的精细生物纳米平台。
Acta Pharmacol Sin. 2017 Jun;38(6):754-763. doi: 10.1038/aps.2017.12. Epub 2017 Apr 10.
10
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.乳腺导管原位癌携带有代表浸润性乳腺癌的突变驱动事件。
Mod Pathol. 2017 Jul;30(7):952-963. doi: 10.1038/modpathol.2017.21. Epub 2017 Mar 24.